Tamoxifen is currently used for the treatment of breast cancer. Response to tamoxifen in metastatic conditions is a primary issue in cancer development. We used a cohort of breast cancer patients, treated or not with tamoxifen, and combined these data with the gene signature of metastatic samples in order to investigate the genetic mechanism of metastasis development, in search of a possible therapeutic effect of tamoxifen in metastatic conditions,. The analysis revealed a group of 21 genes common both to the set of up regulated genes in metastatic BC patients and to the set of down regulated genes in tamoxifen treated patients. These genes could be used as biomarkers for tamoxifen-sensitivity in order to optimize BC treatment

Cava, C., Bertoli, G., Zoppis, I., Mauri, G., Gilardi, M., Castiglioni, I. (2013). Candidate biomarkers for response to tamoxifen in breast cancer metastatic patients. In 13th IEEE International Conference on BioInformatics and BioEngineering, IEEE BIBE 2013; Chania; Greece; 10 November 2013 through 13 November 2013 (pp.1-4). IEEE [10.1109/BIBE.2013.6701636].

Candidate biomarkers for response to tamoxifen in breast cancer metastatic patients

CAVA, CLAUDIA;ZOPPIS, ITALO FRANCESCO;MAURI, GIANCARLO;GILARDI, MARIA CARLA;Castiglioni, I.
2013

Abstract

Tamoxifen is currently used for the treatment of breast cancer. Response to tamoxifen in metastatic conditions is a primary issue in cancer development. We used a cohort of breast cancer patients, treated or not with tamoxifen, and combined these data with the gene signature of metastatic samples in order to investigate the genetic mechanism of metastasis development, in search of a possible therapeutic effect of tamoxifen in metastatic conditions,. The analysis revealed a group of 21 genes common both to the set of up regulated genes in metastatic BC patients and to the set of down regulated genes in tamoxifen treated patients. These genes could be used as biomarkers for tamoxifen-sensitivity in order to optimize BC treatment
slide + paper
biomarkers; data analysis
English
IEEE International Conference on BioInformatics and BioEngineering, IEEE BIBE 10 -13 November
2013
13th IEEE International Conference on BioInformatics and BioEngineering, IEEE BIBE 2013; Chania; Greece; 10 November 2013 through 13 November 2013
978-147993163-7
2013
1
4
6701636
none
Cava, C., Bertoli, G., Zoppis, I., Mauri, G., Gilardi, M., Castiglioni, I. (2013). Candidate biomarkers for response to tamoxifen in breast cancer metastatic patients. In 13th IEEE International Conference on BioInformatics and BioEngineering, IEEE BIBE 2013; Chania; Greece; 10 November 2013 through 13 November 2013 (pp.1-4). IEEE [10.1109/BIBE.2013.6701636].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/50710
Citazioni
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 0
Social impact